Kahn Brothers Group Lowered Seaboard (SEB) Position; Dynavax Technologies (DVAX) Has 0.83 Sentiment

June 20, 2017 - By Linda Rogers

Kahn Brothers Group Inc decreased Seaboard Corp (SEB) stake by 3.56% reported in 2016Q4 SEC filing. Kahn Brothers Group Inc sold 309 shares as Seaboard Corp (SEB)’s stock declined 1.07%. The Kahn Brothers Group Inc holds 8,370 shares with $33.08 million value, down from 8,679 last quarter. Seaboard Corp now has $4.77 billion valuation. The stock increased 0.52% or $21.2 during the last trading session, reaching $4125. About shares traded. Seaboard Corp (NYSEMKT:SEB) has risen 36.88% since June 20, 2016 and is uptrending. It has outperformed by 20.18% the S&P500.

Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The company has market cap of $415.57 million. The Firm is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor stimulation. It currently has negative earnings. The Company’s product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.

Clovis Capital Management Lp holds 1.69% of its portfolio in Dynavax Technologies Corporation for 41,669 shares. New Leaf Venture Partners L.L.C. owns 256,381 shares or 0.73% of their US portfolio. Moreover, Rhenman & Partners Asset Management Ab has 0.37% invested in the company for 485,000 shares. The California-based Redmile Group Llc has invested 0.36% in the stock. Amici Capital Llc, a New York-based fund reported 100,000 shares.

Since January 1, 0001, it had 1 buy, and 0 selling transactions for $24,240 activity.

About 2,833 shares traded. Dynavax Technologies Corporation (DVAX) has declined 63.84% since June 20, 2016 and is downtrending. It has underperformed by 80.54% the S&P500.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: